vs
波士顿科学（BSX）与FISERV INC（FISV）财务数据对比。点击上方公司名可切换其他公司
FISERV INC的季度营收约是波士顿科学的1.0倍（$5.3B vs $5.2B），波士顿科学净利率更高（25.7% vs 15.3%，领先10.4%），波士顿科学同比增速更快（11.6% vs 0.6%），过去两年波士顿科学的营收复合增速更高（12.4% vs 4.0%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
Fiserv是总部位于美国威斯康星州密尔沃基的跨国金融科技企业，面向银行机构提供借记卡、信用卡交易处理、忠诚度计划管理、贷款服务、电子账单支付、电汇及ACH转账、支票存款、ATM交易处理等解决方案，同时生产借记卡、信用卡及POS终端设备。
BSX vs FISV — 直观对比
营收规模更大
FISV
是对方的1.0倍
$5.2B
营收增速更快
BSX
高出11.0%
0.6%
净利率更高
BSX
高出10.4%
15.3%
两年增速更快
BSX
近两年复合增速
4.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $5.3B |
| 净利润 | $1.3B | $811.0M |
| 毛利率 | 69.5% | — |
| 营业利润率 | — | 24.4% |
| 净利率 | 25.7% | 15.3% |
| 营收同比 | 11.6% | 0.6% |
| 净利润同比 | 99.0% | -13.5% |
| 每股收益（稀释后） | $0.90 | $1.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXFISV
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $5.3B | ||
| Q3 25 | $5.1B | $5.3B | ||
| Q2 25 | $5.1B | $5.5B | ||
| Q1 25 | $4.7B | $5.1B | ||
| Q4 24 | $4.6B | $5.3B | ||
| Q3 24 | $4.2B | $5.2B | ||
| Q2 24 | $4.1B | $5.1B |
净利润BSXFISV
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $811.0M | ||
| Q3 25 | $755.0M | $792.0M | ||
| Q2 25 | $795.0M | $1.0B | ||
| Q1 25 | $672.0M | $851.0M | ||
| Q4 24 | $563.0M | $938.0M | ||
| Q3 24 | $468.0M | $564.0M | ||
| Q2 24 | $322.0M | $894.0M |
毛利率BSXFISV
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 68.8% | — | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | — | ||
| Q2 24 | 69.2% | — |
营业利润率BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 24.4% | ||
| Q3 25 | 20.7% | 27.3% | ||
| Q2 25 | 16.2% | 30.7% | ||
| Q1 25 | 19.8% | 27.2% | ||
| Q4 24 | 14.8% | 31.8% | ||
| Q3 24 | 17.4% | 30.7% | ||
| Q2 24 | 12.6% | 28.0% |
净利率BSXFISV
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 15.3% | ||
| Q3 25 | 14.9% | 15.0% | ||
| Q2 25 | 15.7% | 18.6% | ||
| Q1 25 | 14.4% | 16.6% | ||
| Q4 24 | 12.3% | 17.9% | ||
| Q3 24 | 11.1% | 10.8% | ||
| Q2 24 | 7.8% | 17.5% |
每股收益（稀释后）BSXFISV
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $1.51 | ||
| Q3 25 | $0.51 | $1.46 | ||
| Q2 25 | $0.53 | $1.86 | ||
| Q1 25 | $0.45 | $1.51 | ||
| Q4 24 | $0.38 | $1.63 | ||
| Q3 24 | $0.32 | $0.98 | ||
| Q2 24 | $0.22 | $1.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $798.0M |
| 总债务越低越好 | — | $27.8B |
| 股东权益账面价值 | — | $25.8B |
| 总资产 | — | $80.1B |
| 负债/权益比越低杠杆越低 | — | 1.08× |
8季度趋势，按日历期对齐
现金及短期投资BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $798.0M | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $534.0M | $999.0M | ||
| Q1 25 | $725.0M | $1.2B | ||
| Q4 24 | $414.0M | $1.2B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.9B | $1.2B |
总债务BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $27.8B | ||
| Q3 25 | $11.1B | $28.9B | ||
| Q2 25 | $11.1B | $28.1B | ||
| Q1 25 | $10.5B | $27.0B | ||
| Q4 24 | $9.0B | $23.7B | ||
| Q3 24 | $9.2B | $24.1B | ||
| Q2 24 | $9.0B | $24.4B |
股东权益BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $25.8B | ||
| Q3 25 | $23.4B | $25.1B | ||
| Q2 25 | $22.4B | $25.2B | ||
| Q1 25 | $22.2B | $25.9B | ||
| Q4 24 | $21.8B | $27.1B | ||
| Q3 24 | $20.7B | $27.8B | ||
| Q2 24 | $20.4B | $28.2B |
总资产BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $80.1B | ||
| Q3 25 | $42.7B | $79.4B | ||
| Q2 25 | $41.6B | $81.5B | ||
| Q1 25 | $40.1B | $80.4B | ||
| Q4 24 | $39.4B | $77.2B | ||
| Q3 24 | $38.1B | $79.8B | ||
| Q2 24 | $37.1B | $93.4B |
负债/权益比BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 1.08× | ||
| Q3 25 | 0.48× | 1.15× | ||
| Q2 25 | 0.50× | 1.11× | ||
| Q1 25 | 0.47× | 1.04× | ||
| Q4 24 | 0.41× | 0.88× | ||
| Q3 24 | 0.45× | 0.87× | ||
| Q2 24 | 0.44× | 0.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $1.9B |
| 自由现金流经营现金流 - 资本支出 | — | $1.5B |
| 自由现金流率自由现金流/营收 | — | 28.4% |
| 资本支出强度资本支出/营收 | — | 8.4% |
| 现金转化率经营现金流/净利润 | — | 2.40× |
| 过去12个月自由现金流最近4个季度 | — | $4.3B |
8季度趋势，按日历期对齐
经营现金流BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $1.9B | ||
| Q3 25 | $1.3B | $1.8B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $541.0M | $648.0M | ||
| Q4 24 | $1.5B | $2.2B | ||
| Q3 24 | $1.0B | $2.2B | ||
| Q2 24 | $813.0M | $1.3B |
自由现金流BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $1.5B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $354.0M | $313.0M | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $823.0M | $1.8B | ||
| Q2 24 | $658.0M | $993.0M |
自由现金流率BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 28.4% | ||
| Q3 25 | 22.9% | 24.7% | ||
| Q2 25 | 22.3% | 21.5% | ||
| Q1 25 | 7.6% | 6.1% | ||
| Q4 24 | 25.8% | 34.7% | ||
| Q3 24 | 19.6% | 35.2% | ||
| Q2 24 | 16.0% | 19.4% |
资本支出强度BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 8.4% | ||
| Q3 25 | 3.6% | 9.6% | ||
| Q2 25 | 3.1% | 8.7% | ||
| Q1 25 | 4.0% | 6.5% | ||
| Q4 24 | 6.1% | 7.6% | ||
| Q3 24 | 4.3% | 7.7% | ||
| Q2 24 | 3.8% | 6.8% |
现金转化率BSXFISV
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 2.40× | ||
| Q3 25 | 1.78× | 2.28× | ||
| Q2 25 | 1.62× | 1.62× | ||
| Q1 25 | 0.81× | 0.76× | ||
| Q4 24 | 2.59× | 2.37× | ||
| Q3 24 | 2.14× | 3.97× | ||
| Q2 24 | 2.52× | 1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
FISV
| Small Business | $1.7B | 32% |
| Products | $1.0B | 19% |
| Digital Payments | $960.0M | 18% |
| Issuing | $792.0M | 15% |
| Enterprise | $587.0M | 11% |
| Processing | $265.0M | 5% |
| Affiliated Entity | $18.0M | 0% |
